On October 16, the Latvian Medicines Verification System (LZVS) will be updated with the Core release 3.0, which will replace the current one. At the same time, the reporting system will also be renewed by rollout of the new Reporting release 3.0. The maintenance work will start on October 16 at 21:00 and are expected to be completed by lunchtime the following working day. System availability may be interrupted for up to a couple of hours.
Core release 3.0 includes stabilization, optimization, and improvement of the medicines verification system, as well as some functional improvements. A warning about packages from Great Britain (Brexit, non-EU) will be implemented and the validity period of passwords will be extended to 180 days.
The reporting system release 3.0 is intended to improve the usability of the reporting tool, which is used daily by the national competent authorities (Health Inspectorate, State Agency of Medicines) and the Latvian Medicines Verification Organization (LZVO). The approved enhancements of existing NCA reports and new reports will be delivered to the Reporting system, fulfilling the set priorities for 2023 defined by CCB (Change Control Board). Core release 3.0 will not introduce a new version of the end user interface (API), so end user systems will not be affected. LZVS developer Arvato will support the current v4 and v5 versions until fall 2024.
LZVO invites LZVS users together with IT developers to move to the latest version of LZVS interface v5, which provides several functional improvements in daily work with the verification system. The response to the verification request contains information about additional parameters related to the product packaging and whether it is possible to return its status:
• product name,
• the package was decommissioned by the same user - yes/no,
• possibility to return package status (10 days) – yes/no.
Also, the medicines verification system provides the last warning for repeated decommissioning of pack before the alert is generated.